Evaluation of Survivin Reverse Transcriptase-Polymerase Chain Reaction for Noninvasive Detection of Bladder Cancer

Journal of Urology

Volumn 175, Issue 6, 2006, Pages 2312-2316

  Moussa, Omar ^a,b   Abol Enein, Hassan ^d   Bissada, Nabil K ^c   Keane, Thomas ^a   Ghoneim, Mohamed A ^d   Watson, Dennis K ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d NONE

Author keywords

biological; bladder; bladder neoplasms; human; survivin protein; tumor marker

Indexed keywords

MESSENGER RNA; SURVIVIN;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER CARCINOMA; BLADDER CONTRACTION; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; EVALUATION; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY; URINALYSIS; URINARY TRACT DISEASE; URINE SEDIMENT;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 33646529633     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00254-0     Document Type: Article

References (21)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
2. Lotan Y., and Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder. a decision analytical approach. J Urol 167 (2002) 75
3. Moussa O., Szalai G., Abol-Enein H., Bissada N.K., Ghoneim M.A., and Watson D.K. Detection of chromosomal aberrations in transitional cell carcinoma of the bladder by representational difference analysis. Cancer Genet Proteom 1 (2004) 9
4. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46
5. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117
6. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., and Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152 (1998) 43
7. Muscheck M., Abol-Enein H., Chew K., Moore II D., Bhargava V., Ghoneim M.A., et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 21 (2000) 1721
8. Longo M.C., Berninger M.S., and Hartley J.L. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 93 (1990) 125
9. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B. two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097
10. Mulley A.G. Screening the healthy subject. Clin Lab Med 6 (1986) 241
11. Quek M.L., Sanderson K., Daneshmand S., and Stein J.P. New molecular markers for bladder cancer detection. Curr Opin Urol 14 (2004) 259
12. Hakenberg O.W., Fuessel S., Richter K., Froehner M., Oehlschlaeger S., Rathert P., et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64 (2004) 1121
13. Siracusano S., Niccolini B., Knez R., Tiberio A., Benedetti E., Bonin S., et al. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 47 (2005) 327
14. Shariat S.F., Casella R., Monoski M.A., Sulser T., Gasser T.C., and Lerner S.P. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 170 (2003) 2244
15. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324
16. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., and Altieri D.C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341 (1999) 452
17. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004) 626
18. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., and Lee S.E. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171 (2004) 631
19. Munch M., Nielsen L.P., Handberg K.J., and Jorgensen P.H. Detection and subtyping (H5 and H7) of avian type A influenza virus by reverse transcription-PCR and PCR-ELISA. Arch Virol 146 (2001) 87
20. Ryan B., O'Donovan N., Browne B., O'Shea C., Crown J., Hill A.D., et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92 (2005) 120
21. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92 (2005) 212